Track topics on Twitter Track topics that are important to you
HAIFA, Israel, June 14, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange (TASE) to open the weekly trading of the Israeli market, following the announcement of its positive study results.
Pluristem recently announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication, where treatment was found to reduce the incidence of revascularization, improve patients’ mobility and validate the design of the company’s ongoing multinational Phase III study in Critical Limb Ischemia.
The event will take place at the TASE on Sunday, June 17, 2018 at 9:30am Israel time.
Pluristem welcomes its partners, investors and friends to join the event.
Registration is required at: Investor.email@example.com.
Karine Kleinhaus, MD, MPH
Divisional VP, North America
Head of Investor and Public Relations
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...